CelLBxHealth PLC
11 August 2026
CelLBxHealth plc
("CelLBxHealth" or "the Company")
Parsortix CTCs used for Brain Cancer detection
· Independent peer-reviewed study supports Parsortix® use in GBM
· CTC-enriched GBM samples reflect matched tumour genomics
· Findings suggest potential in GBM diagnosis and monitoring
· Study aligned with CelLBxHealth own research data on GBM patient samples
Guildford, UK and Plymouth Meeting, USA - 11 August 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces the publication of a peer-reviewed study in JCO Precision Oncology demonstrating the diagnostic and monitoring potential of Parsortix®-enriched CTCs in patients with glioblastoma ("GBM"), the most common aggressive malignant primary brain tumour in adults.
Key study findings
Researchers at Fondazione Pisana per la Scienza and Ospedali Riuniti di Livorno USL Toscana Nord Ovest, Italy, used the Parsortix® Platform to enrich CTCs from blood samples taken from 27 patients with GBM, alongside healthy controls and non-GBM brain lesion cases. Key findings include:
· First proposed numerical CTC threshold for GBM, where >4 CTCs per 5 mL of blood helped distinguish patients with primary GBM from healthy controls, with 80% sensitivity and 77.3% specificity
· Parsortix-enriched CTCs contained tumour-related mutations and chromosomal changes also seen in matched tumour tissue, indicating that the captured cells reflected the patient's tumour biology
· Single-cell analysis showed that GBM CTCs were highly variable, reflecting known disease complexity
· Radionecrosis and lymphoma samples yielded no detectable CTCs, supporting the use of CTC enumeration in differentiating tumour recurrence from treatment-related change
Although GBM rarely spreads outside the brain, this study adds to growing evidence that tumour-derived cells can be detected in the blood, opening the potential for minimally invasive molecular insight into GBM biology.
In-house GBM research study
At the annual Society for Neuro-Oncology meeting, held on 19-23 November in Hawaii, USA, the Company presented a poster entitled 'Unlocking the potential of liquid biopsy in glioblastoma: an extensive evaluation of circulating biomarkers.' CelLBxHealth's internal GBM research generated findings aligned with this independent study, supporting the potential of Parsortix®-enriched CTCs to provide tumour-related genomic information in a cancer where tissue biopsy is difficult and conventional monitoring approaches are limited.
Lavanya Sivapalan, PhD, CelLBxHealth Chief Scientific Officer, commented: "Glioblastoma remains one of the most difficult cancers to monitor, as repeat tissue sampling requires invasive neurosurgery and imaging can be difficult to interpret, particularly when assessing suspected recurrence. This study provides compelling independent evidence, aligned with our recently presented internal research, that Parsortix®-enriched CTCs can provide biologically relevant information in GBM. The proposed CTC threshold and genomic overlap with matched tumour tissue support further investigation of CTCs as a complementary liquid biopsy approach in this difficult-to-sample disease."
The peer-reviewed manuscript is available online: Lessi F. et al. (2026). Beyond the Brain: Circulating Tumor Cells as a Tool for Diagnosis and Monitoring. JCO Precision Oncology.
For further information:
|
CelLBxHealth plc Jan Groen, Executive Chairman |
investor@cellbxhealth.com via Walbrook PR |
|
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales) |
+44 (0) 20 7220 0500 |
|
Walbrook PR (Investor and Media Relations) Paul McManus / Alice Woodings |
Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development, and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling, and full genomic workflows.
Commercial focus spans three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab-Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.
For more information, visit https://cellbxhealth.com/.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.